2,3-Diphosphoglyceric Acid Changes in Uremia and During Hemodialysis

Article information

Korean J Intern Med. 1986;1(1):86-91

doi : https://doi.org/10.3904/kjim.1986.1.1.86

Sung Kyew Kang, M.D., Sung Kwang Park, M.D.

Department of Internal Medicine, Chonbuk National University Medical School, Korea

Address reprint requests: Sung Kyew Kang, M.D., Division of Nephrology, Dept. of Internal Medicine Chonbuk National University Medical School, Chongju, Chonbuk 520 Korea

Abstract

The present study is an investigation of the mechanism of changes in erythrocyte 2,3-diphosphoglyceric acid (2,3-DPG) in patients with chronic renal failure during hemodialysis.

The study was conducted on 7 Korean and 6 American patients on maintenance hemodialysis. The plasma pH of Korean patients was 7.31±0.02 before hemodialysis and 7.40±0.04 after hemodialysis (p<0.001). The pH of erythrocyte also increased from 7.13±0.02 to 7.20±0.03. The concentration of hemoglobin 2,3-DPG in Korean patients was 10.86±2.89 μmol/g before hemodialysis and 19.93±2.89 μmol/g after hemodialysis (p<0.001).

Similar results were obtained in American patients. Hemoglobin 2,3-DPG was 12.54±2.53 and 18.76±6.73 μmol/g before and after dialysis respectively. Despite the presence of substantial anemia, hemoglobin 2,3-DPG prior to hemodialysis was significantly lower than the values obtained in the normal controls (17.45±4.3 μmol/g).

The blood glucose increased from 93.3±8.5 mg/dl before dialysis to 117.1±6.1 mg/dl after hemodialysis in Korean patients but no significant change was detected in American patients. The increased blood glucose with hemodialysis observed in Korean patients was probably attributable to the lower baseline glucose concentration and the gain of glucose from dialysate, which had a glucose concentration of 186±34.1 mg/dl.

The results suggest that the increase in 2,3-DPG with hemodialysis is probably caused by an increase of pH and an increased glucose utilization.

Keywords: Hemodialysis; Anemia; Red blood cell; 2,3-DPG; Glucose

INTRODUCTION

In chronic anemia, oxygen supply to the vital tissues is facilitated by decreasing the intracorpuscular oxygen binding capacity.

Chronically anemic patients in general show a little or sometimes no systemic symptoms. This suggests that there must be some mechanisms to compensate for the decreased partial pressure to oxygen in arterial blood. One important mechanism is the increase of the concentration of 2,3-diphosphoglyceric acid (2,3-DPG), an intracorpuscular phosphorylated compound resulting in decrease of the oxygen affinity of hemoglobin.^1–3) Thus 2,3-DPG plays an important role in unloading oxygen to the tissues.

Since the introduction of hemodialysis in 1940 by Kolff for the treatment of acute renal failure, not only prolongation of the lifespan of the patients and the return to the social life have became possible, but also many problems following hemodialysis as well as complications of chronic renal failure itself have become evident.

During hemodialysis the patients may experience cardiopulmonary symptoms such as dyspnea, chest discomfort, decrease of blood pressure, arrhythmia, tachycardia and muscle cramp. There are several proposed mechanisms to explain about these symptoms, but they are still controversial.^4–15)

Bergstroem et al.¹⁶⁾ attributed these non-physioligical phenomena to hypovolemia and decrease of plasma osmolarity due to hemodialysis. Rodrigo et al.¹⁷⁾ reported that the patients with stood the dialysis better and had less decrease of plasma osmolarity after changing the glucose concentration in dialysate from 278 to 714 mg/dl.

On observation of electrolytes and biochemical changes in patients with chronic renal failure and on maintenance hemodialysis, authors noticed that despite the severe anemia (hemoglobin 5–9g%), intracorpuscular 2,3-DPG concentration was lower than the normal value, and whole blood and hemoglobin 2-3-DPG concentration increased after hemodialysis. The purpose of this investigation is to determine the mechanism changes in 2,3-DPG in patients with chronic renal failure undergoing hemodialysis treatment.

SUBJECTS AND METHODS

Healthy volunteers without any evidence of kidney disease, 7 males and 4 females between 27 and 60 years of age, served as the control. The study group consisted of 13 patients (7 Korean and 6 American) on maintenance hemodialysis with relatively stable chronic renal failure. They were dialyzed using a hollow fiber dialyzer (Cobe comp.) for 4 hours, 2 to 3 times a week.

Five milliliters of blood samples were collected from the patients before and after dialysis. Blood cell counts were done with the Coulter counter, blood glucose measurement with a Beckman analyzer, intracorpuscular pH measurement by Peter Hilpert method¹⁸⁾ and arterial blood gas analysis with Radiometer-Copenhagen acid-base cart machine. The concentration of 2,3-DPG was measured in accordance with enzymatic methods in Sigma technical bulletin No. 35-UV as follows: One milliliter of blood sample was mixed with 3.0ml of 8% trichloroacetic acid and centrifuged for 10 min. at 3000 rpm to obtain the supernatant. One milliliter of NADH was dissolved in 8.0 ml of 0.2M triethanolamine buffer and 2.5 ml of this NADH solution was mixed with 0.1 ml of ATP and 0.25 ml of supernatant in a 3 ml cuvette.

To this reaction mixture, 0.2ml of GAPD/PGPD (glyceraldehyde-3-phosphate dehydrogenase/phosphoglycerate phosphokinase) and 0.2 ml phosphoglycerate mutase were added. The optical density of the reaction mixture was measured after 5 min. at 340 nm.

One-tenth milliliters of phosphoglycolic acid was added to the above reaction mixture and allowed to stand for 30 min. at room temperature. The optical density was measured again at 340 nm. The blood 2,3-DPG concentration (μmol/ml) thus measured was expressed as μmol per gm of hemoglobin.

RESULTS

1. Concentration of 2,3-DPG of whole blood, packed cells and hemoglobin in control group

The mean hemoglobin and hematocrit value of control groups were 14.2±1.6% and 41.9±4.5%. The mean 2,3-DPG value of whole blood, packed cell and hemoglobin were 2.43±0.6, 5.81±1.4 μmol/ml and 17.45±4.3 μmol/g, respectively (Table 1).

Table 1.

Blood findings and 2,3-diphosphoglycerate level in normal persons

2. The change of partial pressure of arterial blood gas in patients on hemodialysis

Seven out of 13 patients with chronic renal failure showed significant increase of partial pressure of oxygen (pO₂) after hemodialysis. The predialysis PO₂ was 92.3±14.4 but increased to 105.9±14.3 mmHg after dialysis. Partial pressure of CO₂ (PCO₂) showed significant decrease from 31.9±8.5 to 28.4±6.5 mmHg after dialysis (Table 2).

Table 2.

Comparison of blood pH, O₂ tension (PO₂), CO₂ tension (PCO₂), bicarbonate (HCO₃) and intraerythrocyte pH(pHi) in pre-and post chronic hemodialysis patients

3. pH change of whole blood and intraerythrocyte

pH of arterial blood was measured because the change of 2,3-DPG may have been caused by the change of pH. There was a significant increase of pH from predialysis value of 7.31±0.02 to 7.40±0.04 (p<0.01). There was also a significant intraerytrocyte pH change from 7.13±0.02 to 7.20±0.03 (Table 2).

4. Change of 2,3-DPG concentration during hemodialysis in patients with chronic renal failure

The mean predialysis hemoglobin and hematocrit values of 7 Korean patients with chronic renal failure on maintenance hemodialysis were 6.4±1.3g% and 19.4±1.6%, respectively. They showed little clincal symptoms of hypoxia in peripheral tissues. The mean 2,3-DPG value before dialysis was 10.86±2.89 μmol/g (range from 4.73 to 14.15 μmol/g) and increased to 19.93±5.27 μmol/g (range from 12.62 to 28.57 μmol/g) after dialysis. This is very significant increase (p<0.01) (Table 3)

Table 3.

Comparison of BUN, hemoglobin (Hg) and 2,3-diphosphoglycerte (2,3-DPG) in pre-and post chronic hemodialysis patients

5. The relationship of blood glucose and 2,3-DPG changes in hemodialysis patients

The concentration of blood glucose was measured as a function of time during hemodialysis in 7 Korean patients because the change of 2,3-DPG may be caused by the change of blood glucose concentration during the hemodialysis. The results are shown in Figure 1. Predialysis basal value of blood glucose was 98.3±8.5 mg/dl and increased to 114.1±6.5 mg/dl at 15 min. 117.7±3.9 at 30 min. 106.6±2.9 at 60 min. 110.7±4.2 at 120 min and 117.4±6.1 mg/dl at 4 hours of hemodialysis which is higher than the basal level. The glucose concentration of dialysate was 186.1 mg/dl. Therefore, the change of 2,3-DPG concentration was considered to be effected by blood glucose. We also examined the change of blood glucose in 6 American patients with chronic renal failure. The value was 98.5±9.5 mg/dl before dialysis, 105.9±3.9 at 1 hour of dialysis, 105.2±6.5 at 2 hours and 103.1±6.1 mg/dl at 3 hours. The predialysis glucose concentration of American patients was higher than those of Korean patients.

Fig. 1.

Sequential changes of blood glucose level during hemodialysis on chronic renal failure (Korean, N:6).

6. The change of 2,3-DPG concentration after the glucose load in normal controls

To investigate the relationship between the changes of 2,3-DPG and blood glucose, we studied 5 normal controls to determine changes in 2,3-DPG concentration of blood as a function of time after oral administration of 50 gm glucose. The blood glucose at a fasting state was 87.5±2.9 mg/dl and hemoglobin 2,3-DPG was 13.04±1.53 μmol/g, but 145.0±5.2 mg/dl and 13.16±2.66 μmol/g at 1 hour after the glucose change in 2,3-DPG during hemodialysis was a load, 85.0±4.9 mg/dl and 13.39±1.17 μmol/g at 2 hours and 87.5±7.2 mg/dl and 14.73±3.75 μmol/g at 3 hours, respectively.

The comcentration of 2,3-DPG increased in accordance with blood glucose at the first hour and continued increasing while blood glucose returned to a normal level 2 hours after the glucose loading.

DISCUSSION

There was a marked increase of hemoglobin 2,3-DPG concentration after hemodialysis in anemic patients with chronic renal failure. This is thought to be caused by an increase of pH and the blood glucose level effected by dialysate glucose through the dialysis membrane. There are several proposed mechanisms to explain such a rapid increase of intraerythrocyte 2,3-DPG concentration in response to hypoxia. Intraerythrocyte 2,3-DPG, an intermediate of glycolysis, is an organic phosphate converted from 1,3-DPG in Rapoport-Luebering shunt.¹⁹⁾ The increase of 2,3-DPG concentration after hypoxia was caused by either decrease of 2,3-DPG degradation due to inhibition of 2,3-DPG phosphatase or increase of 2,3-DPG synthesis through the accelerated 2,3-DPG mutase reaction. The amount of 2,3-DPG synthesis depends on how much 1,3-DPG entered Rapoport-Luebering cycle and how much 2,3-DPG mutase reacts. The hormones known to increase the intraerythrocyte 2,3-DPG are thyroxine,^20–21) androgen,^22–24) aldosterone^25–26) and glucocorticoid.^27–29) Especially hydrocortisone and thyroxine are known to activate 2,3-DPG mutase and thus increase the conversion of 2,3-DPG from 1,3-DPG^20,29)

In this study the mean 2,3-DPG concentration in patients with chronic renal failure was 10.86±2.89 μmol/g, much less than 17.45±4.3 μmol/g in normal controls. Theoretically, the intraerythrocyte 2,3-DPG level in severe anemic state must be higher than normal controls to compensate for the decreased amount of oxygen available to tissues.³⁰⁾ But there was no clear explanation for this low 2,3-DPG level in anemic patients with chronic renal failure. On the other hand, intraerythrocyte 2,3-DPG concentration increased with hemodialysis by 54.5% from 10.86±2.89 μmol/g to 19.93±5.27 μmol/g. What caused this increase of 2,3-DPG concentration after hemodialysis? Intraerythrocyte pH change had an important role in controlling 2,3-DPG concentration.³¹⁾ In metabolic acidosis the level of 2,3-DPG decreases, and this lowers the oxygen affinity of hemoglobin. In this study the increase of 2,3-DPG may be explained by the fact that intraerythrocyte pH increased from 7.31 of predialysis to 7.40 of postdialysis.

Increase in pH activates phosphfructokinase and pyruvate kinase, resulting in increase 2,3-DPG concentration by inducing the intraerythrocyte glycolysis. Another possible mechanism for the change in 2,3-DPG during hemodialysis was a change in blood glucose. There was a significant increase of blood glucose from 93.3 mg% of predialysis to 117.1 mg% of postdialysis in 7 Korean patients (Fig. 1). We also observed the change of blood glucose and 2,3-DPG during dialysis than baseline in 6 American patients (Fig. 2). The increasing pattern of 2,3-DPG in American patients was similar to that observed in Korean patients, but the glucose levels did not change significantly.

Fig. 2.

Relationship between blood glucose and 2,3-DPG changes in blood, packed cell and hemoglobin with chronic renal failure (American, N:6)

The relatively high glucose concentration of dialysate, 186.1±34.1 mg%, may have produced an increased blood glucose levels of Korean patients, which in turn accelerated the intraerythrocyte glycolysis and increased the 2,3-DPG concentration. There was a significant increase of 2,3-DPG after oral glucose load in 5 normal controls (Fig. 3). The concentration of intraerythrocyte 2,3-DPG continued to increase while blood glucose returned to normal at 120 minutes. It deserves in vitro experiments in the future.

Fig. 3.

Changes in blood, packed cell and hemoglobin 2,3-DPG after glucose loading 50 g/orally in normal persons (N:5).

References

1. Benesch R, Benesch RE. Intracellular organic phosphates as regulators of oxygen release by hemoglobin. Nature 221:618. 1969;

2. Deverdier CH, Garby L, Hjelm M. Intraerythrocytic regulation of tissue oxygen tension. Acta Soc Med Upsal 74:209. 1969;

3. Chanutin A, Curnish RR. Effect of orgnic and inorganic phosphates on the oxygen equilibrium of human erythrocytes. Arch Bioche 121:96. 1967;

4. Kaplow LS, Goffinet JA. Profound JA: Profound neutropenia during early phase of hemodialysis. JAMA 203:1135. 1968;

5. Toren M, Goffinet JA, Kaplow LS. Pulmonary bed sequestration of neutrophils during hemodialysis. Blood 36:337. 1970;

6. Brubaker LH, Nolph KD. Mechanisms of recovery from neutropenia induced by hemodialysis. Blood 38:623. 1971;

7. Sherlock JE, Yoon Y, Ledwith JW, Letteri JM. Respiratory gas exchange during hemodialysis. Proc. Dialysis Transplant. Forum 11:171. 1972;

8. Bischel MD, Scoles BC, Mohler JC. Evidence for pulmonary microembolization during hemodialysis. Chest 67:335. 1975;

9. Craddock PR, Dalmasso Fehr J, Brigham KL, Jocob HS. Hemodialysis leukopenia; Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest 59:897. 1977;

10. Sherlock JE, Ledwith JW, Letterie JM. Hypoventilation and hypoxemia during hemodialysis; Reflex responce to removal of CO₂ across the dialyzer. Trans Am Soc Artif Intern Organs 23:406. 1977;

11. Sherlock JE, Ledwith JW, Letteri JM. Hemodialysis induced hypoxemia; A responce to loss of CO₂ across the dialyzer and increased oxygen consumption. Dialysis Transplant 6:34. 1977;

12. Aurigemma NM, Feldman NT, Gottlieb M, Ingram RH, Lazarus JM, Lowrie FG. Arterial oxygenation during hemodialysis. N Engl J Med 297:871. 1977;

13. Kraut JA, Gafter V, Miller JH, Shmaberger JH. Prevention of arterial hypoxemia during dialysis by use of bicarbonate dialysate. Kidney Int 14:878. 1978;(abstracts).

14. Tolchin N, Roberts JL, Lewis EJ. Respiratory gas exchange by high efficiency hemodialyzers. Nephron 21:137. 1978;

15. Abu-Handan DK, Mahajan SK, Desai S, Choi CW. Hypoxemia during bicarbonate dialysis. Kidney Int 19:140. 1981;

16. Bergstrom J, Asaba H, Fürst P, Oules R. Dialysis, ultrafiltration and blood pressure: in Robinson, Verestracten and Hawkins. Proceedings of the European Dialysis and Transplantation Association 13:293. 1976;

17. Rodrigo F, Shideman J, McHugh R, Buselmeier T, Kjellstrand C. Osmolality changes durings hemodialysis. Natural history, Clinical correlations and influence of dialysate glucose and intravenous mannitol. Ann Intern Med 86:554. 1977;

18. Hilpert P, Fleischmann RG, Kempe D, Bartels H. The Bohr effect related to blood and erythrocyte pH. Am J Physiol 205(2):337. 1963;

19. Rapoport S, Luebering J. Glycerate 2,3-diphosphatase. J Biol Chem 189:683. 1951;

20. Snyder LM, Reddy WJ. Mechanism of action of thyroid hormones on erythrocyte 2,3-diphosphoglyceric acid synthesis. J Clin invest 49:1993. 1970;

21. Miller WW, Papadopoulos MD, Miller L, Oski F. Oxygen releasing factor in hyperthyroidism. JAMA 21:1824. 1970;

22. Molinari PF, Chung SK, Synder LM. Variations of erythrocyte glycolysis following androgens. J clin Med 81:443. 1973;

23. Gorshein D, Oski FA, Papadopulos MD. Effect of androgens on the red cell 2,3-diphosphoglycerate hemoglobin oxygen affinity and red cell mass in mammlsa. Proc Soc Exp Biol Med 147:616. 1974;

24. Parker JP, Beirne GJ, Desai JN, et al. Androgen-induced increase in red cell 2,3-diphosphoglycerate. N Engl J Med 287:381. 1972;

25. Boning D, Meier U, Schweigart U. Diurnal changes of the 2,3-diphosphoglycerate concentration in human red cells and the influence of posture. Europ J Appl Physiol 34:11. 1975;

26. Boning D, Meier U, Skipka W. Some evidence for aldosterone action on 2,3-diphosphoglycerate level in human red cell. Metabolism 25:9. 1976;

27. Petty C, Bageant T. In vitro manipulation of 2,3-diphosphoglycerate levels in acid-citrate-dextrose blood with steroids. Life Science 14:1279. 1974;

28. Silken AB. Pharmacologic manipulation of human erthrocyte 2,3-diphosphoglycerate levels by prednisone administration. Pedia Res 9:61. 1975;

29. Oimoni M, Yoshimura Y, Kubota S, Tanke G, Takagi K, Baba S. Effect of hydrocortison on the synthesis of 2,3-diphosphoglycerate in human erythrocytes. Transfusion 22:266. 1982;

30. Torrance J, Jacobs P, Restrepo A, Eschbach J, Lenfant C, Finch C. Intraerythrocytic adaptation to anemia. N Engl J Med, M 283:165. 1970;

31. Roth M, Astrup P. Dependence of oxyhemoglobin dissociation and intraerythrocytic 2.3-diphosphoglycerate or acid-base states of blood. First international conference on red cell metabolism and function In : Brewer G, ed. New York: Plenum Press; 1969.

32. Minikami S. Effect of oxygen tension on glycolysis in erythrocytes. Försvarsmedicin 5:181. 1969;

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.